Block Copolymer Nanoparticles for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) poses a significant challenge for the delivery of therapeutic agents to the central nervous system (CNS), as it restricts the entry of substances due to tight junctions, enzymatic activity, and efflux systems, making it difficult for exogenously administered drugs and peptides to cross and reach neurological disorders effectively.
Innovation Solution
A pharmaceutical composition comprising a complex of a therapeutic polypeptide and a synthetic block copolymer with a core-shell morphology, where the block copolymer self-assembles into nanoparticles, allowing for site-specific and sustained delivery across the BBB, utilizing a polyion segment with a charge opposite to the polypeptide, which forms stable complexes that can be administered with immune cells to target the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug delivery methods are used, then the blood-brain barrier restricts entry of therapeutic agents, but this prevents effective treatment of neurological disorders
Solution Approach 1:
The patent uses block copolymer nanoparticles as intermediary carriers to transport therapeutic polypeptides across the blood-brain barrier. The nanoparticles with core-shell morphology protect the polypeptide payload and facilitate its passage through the restrictive BBB, enabling effective CNS delivery without direct penetration by the therapeutic agent itself
Solution Approach 2:
The patent modifies the physical and chemical parameters of the therapeutic delivery system by formulating polypeptides into nanoparticle complexes with controlled size, charge, and surface properties. These parameter changes enable the complexes to interact with BBB transport mechanisms and achieve effective brain delivery
2Quantity of substance
If exogenously administered substances are used, then peripheral factors limit presentation and crossing of BBB, but this reduces therapeutic availability
Solution Approach 1:
The patent applies preliminary protective action by encapsulating therapeutic polypeptides within block copolymer nanoparticles before administration. This pre-encapsulation protects the substances from peripheral enzymatic degradation, clearance, and sequestration, ensuring they remain available for BBB crossing and CNS delivery
3Reliability
If nanoparticles are used for delivery, then site-specific and sustained delivery is achieved, but this increases device complexity
Solution Approach 1:
The patent employs segmentation by designing block copolymers with distinct functional segments: a hydrophobic core for polypeptide loading and a hydrophilic shell for stability and biocompatibility. This segmented architecture enables targeted CNS delivery while maintaining relatively simple formulation and synthesis procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide-polyion complexes effectively cross the BBB, delivering therapeutic agents to the CNS, providing neuroprotection and targeting neurological disorders by maintaining enzymatic activity and stability, while avoiding cytotoxicity and aggregation, thus overcoming the limitations of traditional drug delivery methods.
Implementation Method 1
the block copolymer self-assembles into nanoparticles
Implementation Method 2
a synthetic polymer, wherein said synthetic polymer is a block copolymer comprising at least one water soluble, nonionic segment and at least one polyion segment
Implementation Method 3
said polyion segment comprises at least one charge opposite to the charge of the therapeutic polypeptide
Data Source
Figure 1A~1F
Figure 1G
Figure 2A~2B
AI summary
Compositions and methods for the delivery of a protein of interest are provided.